Meta-Analysis of Survival Effects of Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1)
Open Access
Abstract
Background and Objectives: Identification and targeting of membrane proteins in tumor cells is one of the key steps in the development of cancer drugs. The receptor tyrosine kinase-like orphan receptor (ROR) type 1 is a type-I transmembrane protein expressed in various cancer tissues, which is in contrast to its limited expression in normal tissues. These characteristics make ROR1 a candidate target for cancer treatment. This study aimed to identify the prognostic value of ROR1 expression in cancers. Materials and Methods: We conducted a comprehensive systematic search of electronic databases (PubMed) from their inception to September 2021. The included studies assessed the effect of ROR1 on overall survival (OS) and progression-free survival (PFS). Hazard ratios (HR) from collected data were pooled in a meta-analysis using Revman version 5.4 with generic inverse-variance and random effects modeling. Results: A total of fourteen studies were included in the final analysis. ROR1 was associated with worse OS (HR 1.95, 95% confidence interval (CI) 1.50–2.54; p < 0.001) with heterogeneity. The association between poor OS and ROR1 expression was high in endometrial cancer, followed by ovarian cancer, and diffuse large B cell lymphoma. In addition, ROR1 was associated with poor PFS (HR 1.84, 95% CI 1.60–2.10; p < 0.001), but heterogeneity was not statistically significant. In subgroup analysis, high ROR1 expression showed a significantly higher rate of advanced stage or lymph node metastasis. Conclusions: This meta-analysis provides evidence that ROR1 expression is associated with adverse outcome in cancer survival. This result highlights ROR1 as a target for developmental therapeutics in cancers.Keywords
Funding Information
- Hallym University Research Fund (HURF-2021-04, NRF-2020R1G1A1005483, NRF-2022R1F1A1074597, HR21C0198)
- Medical Technology Development Program of the National Research Foundation (NRF) (HURF-2021-04, NRF-2020R1G1A1005483, NRF-2022R1F1A1074597, HR21C0198)
- Korean Government, Ministry of Science and ICT (MSIT) (HURF-2021-04, NRF-2020R1G1A1005483, NRF-2022R1F1A1074597, HR21C0198)
- Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) (HURF-2021-04, NRF-2020R1G1A1005483, NRF-2022R1F1A1074597, HR21C0198)
- Ministry of Health and Welfare (HURF-2021-04, NRF-2020R1G1A1005483, NRF-2022R1F1A1074597, HR21C0198)
This publication has 51 references indexed in Scilit:
- The Onco-Embryonic Antigen ROR1 Is Expressed by a Variety of Human CancersThe American Journal of Pathology, 2012
- Wnt/β-Catenin Signaling and DiseaseCell, 2012
- ROR1 Is Expressed in Human Breast Cancer and Associated with Enhanced Tumor-Cell GrowthPLOS ONE, 2012
- Wnt5a–Ror–Dishevelled signaling constitutes a core developmental pathway that controls tissue morphogenesisProceedings of the National Academy of Sciences, 2012
- Therapeutic Potential and Challenges of Targeting Receptor Tyrosine Kinase ROR1 with Monoclonal Antibodies in B-Cell MalignanciesPLOS ONE, 2011
- 2009 Updated Method Guidelines for Systematic Reviews in the Cochrane Back Review GroupSpine, 2009
- Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5aProceedings of the National Academy of Sciences, 2008
- Measuring inconsistency in meta-analysesBMJ, 2003
- Proteomics in cancer researchInternational Journal of Gynecological Cancer, 2002
- Mutation of β-catenin gene in endometrial cancer but not in associated hyperplasiaMedical Molecular Morphology, 2002